Table 2 Comparison of HER2 status with clinicopathological parameters of patients with UBC (n = 103)
From: Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma
HER2 protein overexpression NO. (%) of cases | P-value | ||
|---|---|---|---|
Absent | Present | ||
Age (median, interquartile range, years) | 64 [55.5–74] | 60 [59.5–70.5] | 0.85 |
Sex | |||
Men | 85 (82.5) | 11 (10.7) | |
Women | 6 (5.8) | 1 (1) | 0.59 |
Tumor size | |||
< 3 cm | 40 (38.3) | 3 (2.9) | |
≥ 3 cm | 51 (49.5) | 9 (8.8) | 0.21 |
Papillary architecture | |||
Absent | 29 (28.2) | 7 (6.8) | |
Present | 62 (60.2) | 5 (4.8) | 0.1 |
Carcinoma in situ | |||
Absent | 89 (86.4) | 12 (11.6) | |
Present | 2 (2%) | 0 (0) | 1 |
Tumor grade | |||
Low | 65 (63.1) | 3 (2.9) | |
High | 26 (25.2) | 9 (8.7) | 0.003 |
Micropapillary differentiation | |||
Absent | 89 (86.3) | 11 (10.7) | |
Present | 2 (2) | 1 (1) | 0.31 |
T stage | |||
≤ pT1 | 76 (73.8) | 6 (5.8) | |
>pT1 | 15 (14.6) | 6 (5.8) | 0.015 |